Inhibitor Therapeutics Secures $3M Financing at Significant Premium to Market Price
INTI has more than doubled off its 52-week low of $0.034 on elevated volume (3.2× avg).
Summary
Inhibitor Therapeutics, a pre-revenue company, has entered into a definitive agreement to raise $3 million through the sale of common stock and warrants to an institutional investor, with the offering priced at a significant premium to the current market.
Key Events · Financing and Capital Events · INTI
-
Securities Purchase Agreement Signed
On February 19, 2026, Inhibitor Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor.
-
Capital Raise Details
The company agreed to sell 12,000,000 shares of common stock and issue warrants to purchase up to 7,000,000 additional shares, for an initial investment of $3,000,000.
-
Premium Pricing
The offering price for the common stock and accompanying warrant is $0.25 per unit, which is a substantial premium to the current stock price of $0.0798.
-
Warrant Terms
The warrants are exercisable for three years at a price of $0.35 per share, potentially generating an additional $2,450,000 in gross proceeds if fully exercised.
Analysis · INTI · Life Sciences
This 8-K reports a critical financing event for Inhibitor Therapeutics, a pre-revenue life sciences company. The agreement to raise $3 million, with potential for an additional $2.45 million from warrant exercises, provides substantial capital for working capital and general corporate purposes. Crucially, the offering price of $0.25 per unit (common stock plus warrants) is a significant premium compared to the current stock price of $0.0798. This premium pricing, despite the potential for substantial dilution from the 12 million shares and 7 million warrants, signals strong institutional investor confidence in the company's future valuation and provides a vital lifeline for its operations. Investors should monitor the closing and funding of this transaction.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INTI was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $0.03 to $0.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.